Neurokinin Receptor Antagonists: Broad Therapeutic Potential Beyond Anti-Nausea Use | Research

The takeaway

Despite the tachykinin system's involvement in cancer, pain, itch, obesity, and more, only five NK-1 receptor antagonists are approved — all for nausea — leaving vast therapeutic potential untapped.

Only 5 approved, all for nausea
Despite NK receptor involvement in cancer, pain, itch, obesity, and dozens more conditions

What the researchers found

Only 5 NK-1R antagonists are clinically approved (all for emesis) despite the tachykinin system's involvement in cancer, pain, itch, obesity, and numerous other conditions — representing significant therapeutic underexploration.

Why it matters

Blocking neuropeptide signaling through NK receptors could treat conditions from cancer to chronic itch, but these drugs remain almost exclusively used for nausea — a missed therapeutic opportunity.

The numbers in context

5 approved NK-1R antagonists; 0 NK-2R/NK-3R approved; patents cover: cancer, pruritus, cardiomyopathy, respiratory, infection, eye, weight, fear, hot flashes, reproduction

How the study worked

Patent review covering NK receptor antagonist inventions and clinical applications from 2014 to 2020.

Who was studied

Patent review of NK-1, NK-2, NK-3 receptor antagonists (2014-present)

What this study cannot tell us

Patent review format — focuses on inventions rather than clinical evidence strength; many proposed applications remain preclinical; reasons for limited clinical translation not fully analyzed.

How to read the evidence

Patent review providing broad overview but limited evidence assessment; most proposed therapeutic applications lack robust clinical trial data.

When this study was published

Published in 2020; NK-3 receptor antagonists for hot flashes (like fezolinetant) have since advanced toward approval.

The bigger picture

The gap between the broad biological roles of tachykinin neuropeptides and the narrow clinical use of their antagonists represents one of the larger missed opportunities in neuropeptide-based medicine.

Questions still open

Why have NK receptor antagonists failed to gain approval beyond anti-emetic indications?
Could NK-1R antagonists like aprepitant be repurposed for cancer or chronic itch?
Will NK-3R antagonists ever reach approval for hot flashes or reproductive disorders?

Common questions

What are neurokinin receptor antagonists used for?

Currently only approved for nausea prevention (anti-emetics), but research suggests they could treat cancer, chronic itch, pain, obesity, and many other conditions involving tachykinin neuropeptides.

Why are substance P blockers not used for more conditions?

Despite strong preclinical evidence, NK receptor antagonists have not been adequately tested in clinical trials for most potential applications, limiting their approved uses to nausea.

Read the original research

Neurokinin receptor antagonism: a patent review (2014-present).

Expert opinion on therapeutic patents, 30(7), 527-539

View on PubMed ↗Publisher’s paper ↗

Citation

Muñoz, Miguel; Coveñas, Rafael. (2020). Neurokinin receptor antagonism: a patent review (2014-present).. Expert opinion on therapeutic patents, 30(7), 527-539. https://doi.org/10.1080/13543776.2020.1769599